Decibel Therapeutics Reports Third Quarter 2021 Financial Results and Corporate Update
10 nov. 2021 07h30 HE
|
Decibel Therapeutics, Inc.
- Received Orphan Drug and Rare Pediatric Disease designations for DB-OTO for the treatment of otoferlin-related congenital hearing loss – - On track for key 2022 milestones including submission of...
Decibel Therapeutics to Present at the Barclays Gene Editing & Gene Therapy Summit
08 nov. 2021 07h00 HE
|
Decibel Therapeutics, Inc.
BOSTON, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and...
Decibel Therapeutics Receives Orphan Drug and Rare Pediatric Disease Designations for DB-OTO for the Treatment of Otoferlin-Related Congenital Hearing Loss
09 sept. 2021 07h30 HE
|
Decibel Therapeutics, Inc.
BOSTON, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore...
Decibel Therapeutics Appoints Cynthia Hu as Chief Legal Officer and Corporate Secretary
18 août 2021 07h30 HE
|
Decibel Therapeutics, Inc.
BOSTON, Aug. 18, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and...
Decibel Therapeutics Reports Second Quarter 2021 Financial Results and Corporate Update
10 août 2021 07h30 HE
|
Decibel Therapeutics, Inc.
- Bolstered Board of Directors and Scientific Advisory Board with key appointments - - On track for anticipated 2022 milestones including submission of IND and/or CTA for DB-OTO and interim...
Decibel Therapeutics Appoints Dr. William H. Carson as Chairman of the Board of Directors
02 juin 2021 08h30 HE
|
Decibel Therapeutics, Inc.
BOSTON, June 02, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and...
Decibel Therapeutics to Present at the UBS Global Healthcare Virtual Conference
19 mai 2021 08h00 HE
|
Decibel Therapeutics, Inc.
BOSTON, May 19, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and...
Decibel Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference
08 avr. 2021 08h00 HE
|
Decibel Therapeutics, Inc.
BOSTON, April 08, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore...
Decibel Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Update
29 mars 2021 16h05 HE
|
Decibel Therapeutics, Inc.
-Successfully completed an oversubscribed Series D financing and upsized Initial Public Offering raising approximately $220.1M in gross proceeds- -Established development and manufacturing agreement...
Decibel Therapeutics Added to Russell 2000 Index
22 mars 2021 08h00 HE
|
Decibel Therapeutics, Inc.
BOSTON, March 22, 2021 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX) (“Decibel”), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments...